Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma

Tsiaousidou, Anastasia; Tsaroucha, Alexandra; Lambropoulou, María; Pitiakoudis, Michail; Polychronidis, Alexandros; Chatzitheoklitos, Efthimios; Romanidis, Κonstantinos; Simopoulos, C.

doi:10.1007/s10238-015-0352-7

Cited by 7 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been suggested that B7-H4 be included in panels of markers involved in cancer stem cell maintenance [18]. In pancreatic cancer, B7-H4 was a negative prognostic marker, indicating more resistance to chemotherapy with gemcitabine [19]. In breast cancer, B7-H4 was highly expressed in both breast cancer and stroma cells, independently of the intrinsic subtypes of breast cancer [20].…”

Section: Discussionmentioning

confidence: 99%

Expression of B7–H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas

et al. 2021

View full text Add to dashboard Cite

High-grade serous ovarian carcinoma (HGSC) is the most lethal gynecologic malignancy. While immune checkpoint inhibitors against PD-L1 and CTLA-4 have shown significant effects in multiple tumor types, the response rate to single-agent immune checkpoint inhibitors is low in HGSC. Alternative biomarkers and targets must be identified to guide patient selection and new therapeutic strategies in HGSC. Here, we aim to investigate the clinical significance of novel immune modulators, including B7-H4, IDO1, Tim3, IL6, and IL-8, in patients with HGSC. A total of 48 patients with HGSCs, comprising 24 cases that were sensitive and 24 that were resistant to standard paclitaxel and carboplatin chemotherapy, were selected for our initial analysis. A NanoString assay including 33 immune-related genes was used to compare the expression of different immune regulatory molecules in the sensitive and resistant groups. Differentially expressed proteins were verified using multiplex immunohistochemical staining on tissue arrays of 202 patients with HGSCs who underwent primary surgery at MDACC. We analyzed the expression levels of immune checkpoints and compared expression profiles with clinicopathologic features including response, progression-free survival, and overall survival. HGSC tumors resistant to therapy expressed higher levels of B7-H4 (69.3%), IDO1 (71.8%), Tim3 (89.1%) and inflammatory factors IL-6 and IL-8 and expressed higher Tim3 in stromal components. High

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of B7–H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Manual review of the reference lists of retrieved manuscripts concerning B7H1 or B7H4 expression in pancreatic cancer yielded four additional studies that met the inclusion criteria for this meta-analysis. However, 16 studies [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] were finally selected for metaanalysis after the removal of duplicates and the application of eligibility criteria.…”

Section: Methodsmentioning

confidence: 99%

The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis

Chen

et al. 2019

Int J Biol Markers

View full text Add to dashboard Cite

Objective: The clinical implications of B7H1 and B7H4 in pancreatic cancer have been described however, the prognostic significance of these genes in pancreatic cancer patients remains inconclusive. The aim of the present study was to evaluate the prognostic role of B7H1 and B7H4 in pancreatic cancer patients. Methods: Electronic databases (PubMed, EMBASE, and the Cochrane Library) were searched for relevant articles published before May 2019. Meta-analyses were performed by pooling the hazard ratios (HRs) between overall survival or cancer-specific survival and high or low expression of B7H1/B7H4 in pancreatic cancer patients. Subgroup and sensitivity analyses were performed, and sources of variabilities were explored by performing meta-regression. Results: Sixteen studies (1434 patients’ data) were included. Compared with low expression, high expression of B7H1 was associated with significantly poor overall survival (HR 1.92 (95% confidence interval (CI) 1.35, 2.74); P<0.001) and cancer-specific survival (HR 2.46 (95% CI 1.55, 3.90); P<0.001). High expression of B7H4 also predicted poor overall survival (HR 2.38 (95% CI 1.89, 3.00); P<0.001). In subgroup analyses, a significant association between B7H1 and overall survival was observed for trials conducted in China (HR 2.08 (95% CI 1.29, 3.34)) but not in Japan (HR 1.98 (95% CI 1.33, 2.96)); or in studies with <50% patients having high expression (HR 2.02 (95% CI 1.40, 2.91)) but not in studies with >50% patients with high expression (HR 1.40 (95% CI 0.87, 2.26)). Conclusion: The current study suggests that high B7H1 and B7H4 expression is associated with a poor prognosis in pancreatic cancer patients.

show abstract

“…The studies were published between 2007 and 2023. They consisted of the following cancer types: OS-osteosarcoma [27], Pca-prostate cancer [28,29], CvC-cervical cancer [30,31], CCA-cholangiocarcinoma [13,32], PDAC-pancreatic ductal adenocarcinoma [33][34][35][36], UCC-urothelial cell carcinoma [36], HNSCC-head and neck squamous cell carcinoma [37,38], OC-ovarian cancer [39], ESCC-esophageal squamous cell carcinoma [28,40], BC-breast cancer [41,42], GC-gastric cancer [43,44], ECC-endometrial cancer [45], NSCLC-non-squamous cell lung carcinoma [46,47], RCC-renal cell carcinoma [48], and CRC-colorectal cancer [39,[49][50][51][52]. The sample sizes ranged from 37 to 996, with a total of 6357 patients.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

Prognostic Value of B7H4 Expression in Patients with Solid Cancers: A Systematic Review and Meta-Analysis

Dawidowicz,

Kula,

Mielcarska

et al. 2024

IJMS

View full text Add to dashboard Cite

V-set domain-containing T-cell activation inhibitor 1 (aliases VTCN1, B7H4) participates in tumour immune escape by delivering inhibitory signals to T cells. The purpose of this article was to assess the B7H4 prognostic value in solid cancers. Three databases were searched for relevant articles. The main endpoints were overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS). Appropriate hazard ratios (HRs) were pooled. The R studio software (version 4.0.3) was used for data analysis. Thirty-one studies met the inclusion criteria. High expression of B7H4 was associated with worse OS (HR = 1.52, 95% CI: 1.37–1.68) but not with DSS (HR = 1.14, 95% CI: 0.49–2.63), RFS (HR = 1.77, 95% CI: 0.75–4.18), DFS (HR = 1.29, 95% CI: 0.8–2.09), or PFS (HR = 1.71, 95% CI: 0.91–3.2) in patients with solid cancers. High expression of B7H4 is associated with a poorer prognosis in patients with solid cancers. B7H4 is a promising prognostic biomarker and immunotherapeutic target for various solid cancers because of its activity in cancer immunity and tumourigenesis.

show abstract

Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma

Cited by 7 publications

References 20 publications

Expression of B7–H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas

Expression of B7–H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas

The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis

Prognostic Value of B7H4 Expression in Patients with Solid Cancers: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About